4-(1H)-quinolones and 1,2,3,4-tetrahydroacridin-9(10H)-ones prevent the transmission of Plasmodium falciparum to Anopheles freeborni

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6187-6195

  Sáenz, Fabián E ^a,b   LaCrue, Alexis N ^a   Cross, R Matthew ^a,c   Maignan, Jordany R ^a   Udenze, Kenneth O ^a   Manetsch, Roman ^a   Kyle, Dennis E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ICI 56780; P 4Q 105; P 4Q 146; P 4Q 95; QUINOLONE DERIVATIVE; THA 93; UNCLASSIFIED DRUG; ACRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANOPHELES; ANOPHELES FREEBORNI; ANTIMALARIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FEMALE; GAMETOCYTE; MOUSE; NONHUMAN; OOCYST; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SALIVARY GLAND; SINGLE DRUG DOSE; SPOROZOITE; ANIMAL; DISEASE CARRIER; DRUG EFFECTS; DRUG SENSITIVITY; GROWTH, DEVELOPMENT AND AGING; HUMAN; LIFE CYCLE STAGE; MALARIA; MALARIA, FALCIPARUM; MALE; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM BERGHEI; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TRANSMISSION;

ACRIDINES; ANIMALS; ANOPHELES; ANTIMALARIALS; FEMALE; HUMANS; INSECT VECTORS; LIFE CYCLE STAGES; MALARIA; MALARIA, FALCIPARUM; MALE; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; QUINOLONES; SALIVARY GLANDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887476008     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00492-13     Document Type: Article

References (48)

1. World Health Organization. 2012. World malaria report 2012. World Health Organization, Geneva, Switzerland.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217.
3. Wells TN, Alonso PL, Gutteridge WE. 2009. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 8:879-891.
4. White NJ, Olliaro P. 1998. Artemisinin and derivatives in the treatment of uncomplicated malaria. Med. Trop. (Mars.) 58:54-56.
5. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431.
6. World Health Organization. 2011. World malaria report 2011. World Health Organization, Geneva, Switzerland.
7. Escalante AA, Smith DL, Kim Y. 2009. The dynamics of mutations associated with anti-malarial drug resistance in Plasmodium falciparum. Trends Parasitol. 25:557-563.
8. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C, Sauerwein R, Ghani AC, Drakeley C. 2010. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 9:136. doi:10.1186/1475-2875-9-136.
9. Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GA. 2006. The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol. 22:424-430.
10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
11. Fidock DA. 2010. Drug discovery: priming the antimalarial pipeline. Nature 465:297-298.
12. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF, Marti M. 2011. A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J. Infect. Dis. 203:1445-1453.
13. Salzer WT, Andersag HA. 1948. A new type of compounds active against avian malaria. Chem. Ber. 81:12-19.
14. Puri SK, Dutta GP. 1990. Quinoline esters as potential antimalarial drugs: effect on relapses of Plasmodium cynomolgi infections in monkeys. Trans. R. Soc. Trop. Med. Hyg. 84:759-760.
15. Ryley JF, Peters W. 1970. The antimalarial activity of some quinolone esters. Ann. Trop. Med. Parasitol. 64:209-222.
16. Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R. 2010. Endochin optimization: structure-activity and structureproperty relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J. Med. Chem. 53:7076-7094.
17. Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R. 2011. Optimization of 1, 2, 3, 4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J. Med. Chem. 54:4399-4426.
18. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA. 2011. Imaging of Plasmodium liver stages to drive nextgeneration antimalarial drug discovery. Science 334:1372-1377.
19. Biagini GA, Fisher N, Shone AE, Mubaraki MA, Srivastava A, Hill A, Antoine T, Warman AJ, Davies J, Pidathala C, Amewu RK, Leung SC, Sharma R, Gibbons P, Hong DW, Pacorel B, Lawrenson AS, Charoensutthivarakul S, Taylor L, Berger O, Mbekeani A, Stocks PA, Nixon GL, Chadwick J, Hemingway J, Delves MJ, Sinden RE, Zeeman AM, Kocken CH, Berry NG, O'Neill PM, Ward SA. 2012. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc. Natl. Acad. Sci. U. S. A. 109:8298-8303.
20. Pidathala C, Amewu R, Pacorel B, Nixon GL, Gibbons P, Hong WD, Leung SC, Berry NG, Sharma R, Stocks PA, Srivastava A, Shone AE, Charoensutthivarakul S, Taylor L, Berger O, Mbekeani A, Hill A, Fisher NE, Warman AJ, Biagini GA, Ward SA, O'Neill PM. 2012. Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2). J. Med. Chem. 55:1831-1843.
21. Winter R, Kelly JX, Smilkstein MJ, Hinrichs D, Koop DR, Riscoe MK. 2011. Optimization of endochin-like quinolones for antimalarial activity. Exp. Parasitol. 127:545-551.
22. Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK. 2008. Antimalarial quinolones: synthesis, potency, and mechanistic studies. Exp. Parasitol. 118:487-497.
23. Cross RM, Namelikonda NK, Mutka TS, Luong L, Kyle DE, Manetsch R. 2011. Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones. J. Med. Chem. 54:8321-8327.
24. Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK. 2012. Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J. Med. Chem. 55:4205-4219.
25. Zhang Y, Guiguemde WA, Sigal M, Zhu F, Connelly MC, Nwaka S, Guy RK. 2010. Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones. Bioorg. Med. Chem. 18:2756-2766.
26. LaCrue AN, Sáenz FE, Cross RM, Udenze KO, Monastyrskyi A, Stein S, Mutka TS, Manetsch R, Kyle DE. 2013. 4(1H)-Quinolones with liver stage activity 1 against Plasmodium berghei. Antimicrob. Agents Chemother. 57:417-424.
27. Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, London WT, Corcoran LM, Burkot TR, Carter R. 1987. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236: 1661-1666.
28. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
29. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, van der Keur M, van der Linden R, Sinden RE, Waters AP, Janse CJ. 2004. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. Parasitol. 137:23-33.
30. Ponnudurai T, Meuwissen JH, Leeuwenberg AD, Verhave JP, Lensen AH. 1982. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans. R. Soc. Trop. Med. Hyg. 76:242-250.
31. Saenz FE, Balu B, Smith J, Mendonca SR, Adams JH. 2008. The transmembrane isoform of Plasmodium falciparum MAEBL is essential for the invasion of Anopheles salivary glands. PLoS One 3:e2287. doi:10.1371/journal.pone.0002287.
32. Ponnudurai T, Billingsley PF, Rudin W. 1988. Differential infectivity of Plasmodium for mosquitoes. Parasitol. Today 4:319-321.
33. Lucantoni L, Yerbanga RS, Lupidi G, Pasqualini L, Esposito F, Habluetzel A. Transmission blocking activity of a standardized neem (Azadirachta indica) seed extract on the rodent malaria parasite Plasmodium berghei in its vector Anopheles stephensi. Malar. J. 9:66. doi:10.1186/1475-2875-9-66.
34. LaCrue AN, Sivaguru M, Walter MF, Fidock DA, James AA, Beerntsen BT. 2006. A ubiquitous Plasmodium protein displays a unique surface labeling pattern in sporozoites. Mol. Biochem. Parasitol. 148:199-209.
35. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
36. Kikuth W, Mudrow-Reichenow L. 1947. Über kausalprophylaktisch bei Vogelmalaria wirksame Substanzen. Zeitschrift für Hygiene und Infektionskrankheiten, medizinische Mikrobiologie. Z Hyg. Infektionskr. 127: 151-165.
37. Salzer G. 1948. Über einen neuen, gegen Vogelmalaria wirksamen Verbindungstypus. Wien Klin. Wochenschr. 60:818.
38. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9:e1001169. doi:10.1371/journal.pmed.1001169.
39. Rupp I, Bosse R, Schirmeister T, Pradel G. 2008. Effect of protease inhibitors on exflagellation in Plasmodium falciparum. Mol. Biochem. Parasitol. 158:208-212.
40. Ojo KK, Pfander C, Mueller NR, Burstroem C, Larson ET, Bryan CM, Fox AM, Reid MC, Johnson SM, Murphy RC, Kennedy M, Mann H, Leibly DJ, Hewitt SN, Verlinde CL, Kappe S, Merritt EA, Maly DJ, Billker O, Van Voorhis WC. 2012. Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J. Clin. Invest. 122:2301-2305.
41. Huho BJ, Killeen GF, Ferguson HM, Tami A, Lengeler C, Charlwood JD, Kihonda A, Kihonda J, Kachur SP, Smith TA, Abdulla SM. 2012. Artemisinin-based combination therapy does not measurably reduce human infectiousness to vectors in a setting of intense malaria transmission. Malar. J. 11:118. doi:10.1186/1475-2875-11-118.
42. Coleman RE, Nath AK, Schneider I, Song GH, Klein TA, Milhous WK. 1994. Prevention of sporogony of Plasmodium falciparum and P. berghei in Anopheles stephensi mosquitoes by transmission-blocking antimalarials. Am. J. Trop. Med. Hyg. 50:646-653.
43. Krungkrai J. 2004. The multiple roles of the mitochondrion of the malarial parasite. Parasitology 129:511-524.
44. Krungkrai J. 1995. Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite. Biochim. Biophys. Acta 1243:351-360.
45. Learngaramkul P, Petmitr S, Krungkrai SR, Prapunwattana P, Krungkrai J. 1999. Molecular characterization of mitochondria in asexual and sexual blood stages of Plasmodium falciparum. Mol. Cell. Biol. Res. Commun. 2:15-20.
46. Krungkrai J, Prapunwattana P, Krungkrai SR. 2000. Ultrastructure and function of mitochondria in gametocytic stage of Plasmodium falciparum. Parasite 7:19-26.
47. Hino A, Hirai M, Tanaka TQ, Watanabe Y, Matsuoka H, Kita K. 2012. Critical roles of the mitochondrial complex II in oocyst formation of rodent malaria parasite Plasmodium berghei. J. Biochem. 152:259-268.
48. Boysen KE, Matuschewski K. 2011. Arrested oocyst maturation in Plasmodium parasites lacking type II NADH:ubiquinone dehydrogenase. J. Biol. Chem. 286:32661-32671.